About HEARTFLOW
HeartFlow is transforming the diagnosis and management of coronary artery disease (CAD) worldwide through its AI-powered analysis platform. The company's vision is to transform CAD from the leading cause of death into a disease that can be managed for life. HeartFlow's first-of-its-kind AI analysis creates detailed 3D models of the heart from coronary computed tomography angiography (CCTA) scans, providing a window into patients' futures and empowering clinicians with insights to personalize each treatment journey. The HeartFlow One platform combines three core analysis capabilities: Roadmap Analysis for efficient and accurate CAD detection, FFR CT Analysis to assess blood flow and determine revascularization benefit, and Plaque Analysis to quantify and characterize plaque for risk stratification and disease management. This comprehensive approach addresses the limitations of conventional diagnostic methods, which have 20-30% false negative rates leading to undetected disease and 55% false positive rates resulting in unnecessary procedures. HeartFlow has treated over 650,000 patients across more than 1,800 institutions globally, with 99.5% of US lives covered by reimbursement. The platform is backed by over 625 peer-reviewed publications demonstrating clinical validity and improved patient outcomes. HeartFlow serves cardiologists, radiologists, and healthcare systems seeking to build efficient and scalable CCTA programs with comprehensive clinical, operational, technical, and financial support.
Mission & Story
Mission
Heartflow's vision is to transform CAD from the leading cause of death into a disease that can be managed for life
Clinical Focus
Medical conditions and clinical areas addressed by HEARTFLOW.
Who It Serves
Milestones & Awards
Recent Milestones
Heartflow Plaque Analysis supported by scientific statements from American College of Cardiology and American Heart Association. AHA 2025 late-breaking data reinforced prognostic power of AI-driven Plaque Analysis. Expanded evidence base across heart disease care continuum from precision risk stratification to CT-guided intervention planning.
Awards & Recognition
Heartflow Plaque Analysis recognized by ACC and AHA scientific statements for personalized management of patients with suspected CAD
Company Details
- Headquarters
- San Francisco, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.